🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Antenatal Melatonin Supplementation for Neuroprotection in Fetal Growth Restriction

RecruitingPhase 3Ages 18 Years - anyFemaleMonash University
NCT05651347 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Fetal growth restriction (FGR) is a significant health care issue, affecting 20,000 Australian pregnancies every year. Undetected FGR is one of the key risk factors for stillbirth, but FGR can also cause significant impairments in short and long-term health outcomes for the child. It is a major risk factor for preterm birth and is a recognised causal pathway to the neurodevelopmental injury underlying cognitive and behavioural impairment and cerebral palsy. Current obstetric care is focused on the detection of the growth restricted fetus and then ultrasound assessment of fetal wellbeing to guide timing of delivery. This approach seeks to maximize the gestational age of the fetus at delivery to minimise the risks of prematurity, while delivering the fetus in time to reduce the likelihood of stillbirth. Currently, no therapies exist that can maximize fetal wellbeing in the setting of grow

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: 1. Singleton Pregnancy 2. Severe fetal growth restriction, defined as: * Abdominal circumference ≤3rd centile for gestational age according to charts supplied that have been adapted from Westerway et al; or * Abdominal circumference \<10th centile in combination with at least one abnormal fetoplacental Doppler study, being: * Uterine artery (raised pulsatility index ≥95th centile) * Umbilical artery (pulsatility index ≥95th centile or absent/reversed end-diastolic flow) 3. Confirmed 23+0 - 31+6 weeks' gestation 4. Age ≥18 years 5. Understand English Exclusion Criteria: 1. A fetus with a known chromosomal, major structural anomaly or non-placental cause of fetal growth restriction 2. Pregnancies requiring immediate delivery (e.g. absent A wave in ductus venosus, preterminal CTG or biophysical profile) 3. Co-recruitment in another clinical trial where a pharmaceutical product or nutritional supplement impacting on oxidative stress is the trial intervention. 4. Currently prescribed Fluvoxamine
💊

What it tests

  • Placebo
  • Melatonin 10 MG
📍

Where

12 sites
Royal Prince Alfred
Camperdown, Australia
John Hunter Hospital
Newcastle, Australia
Mater Misericordiae
South Brisbane, Australia
Gold Coast University Hospital
Southport, Australia
Women's and Children's Hospital
North Adelaide, Australia
Monash Health
Clayton, Australia
Mercy Hospital
Heidelberg, Australia
Royal Women's Hospital
Parkville, Australia

…and 4 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy